[go: up one dir, main page]

SK6172000A3 - Use of macrolides for the treatment of cancer and macular degeneration - Google Patents

Use of macrolides for the treatment of cancer and macular degeneration Download PDF

Info

Publication number
SK6172000A3
SK6172000A3 SK617-2000A SK6172000A SK6172000A3 SK 6172000 A3 SK6172000 A3 SK 6172000A3 SK 6172000 A SK6172000 A SK 6172000A SK 6172000 A3 SK6172000 A3 SK 6172000A3
Authority
SK
Slovakia
Prior art keywords
substituted
heteroaryl
defined above
alkyl
group
Prior art date
Application number
SK617-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Yat Sun Or
Jacob J Plattner
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of SK6172000A3 publication Critical patent/SK6172000A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
SK617-2000A 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration SK6172000A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96147397A 1997-10-31 1997-10-31
PCT/US1998/023043 WO1999022722A2 (fr) 1997-10-31 1998-10-30 Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire

Publications (1)

Publication Number Publication Date
SK6172000A3 true SK6172000A3 (en) 2001-03-12

Family

ID=25504514

Family Applications (1)

Application Number Title Priority Date Filing Date
SK617-2000A SK6172000A3 (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration

Country Status (17)

Country Link
EP (1) EP1027060A2 (fr)
JP (1) JP2001521891A (fr)
KR (1) KR20010031577A (fr)
CN (1) CN1278178A (fr)
AR (1) AR043071A1 (fr)
AU (1) AU1206799A (fr)
BG (1) BG104436A (fr)
BR (1) BR9813318A (fr)
CA (1) CA2307850A1 (fr)
HU (1) HUP0100012A3 (fr)
IL (1) IL135518A0 (fr)
NO (1) NO20002189L (fr)
PL (1) PL340604A1 (fr)
SK (1) SK6172000A3 (fr)
TR (1) TR200001147T2 (fr)
WO (1) WO1999022722A2 (fr)
ZA (1) ZA989885B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079520A1 (fr) 2000-04-13 2001-10-25 Biotica Technology Limited Produits hybrides glycosyles, production et utilisation
US8163726B2 (en) 2002-09-18 2012-04-24 University Of Pennsylvania Method of inhibiting choroidal neovascularization
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
CA2520732C (fr) 2003-03-28 2012-12-04 Sloan-Kettering Institute For Cancer Research Analogues de migrastatine et leurs utilisations
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
KR20060085246A (ko) 2003-09-18 2006-07-26 마커사이트, 인코포레이티드 경공막 전달
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
EP2716647A3 (fr) * 2004-02-27 2014-08-20 Rib-X Pharmaceuticals, Inc. Composes Macrocycliques Et Leurs Procedes De Fabrication Et D'utilisation
CN108101948A (zh) * 2004-02-27 2018-06-01 瑞伯-X医药品有限公司 大环化合物以及其制作和使用方法
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
WO2006034478A2 (fr) 2004-09-23 2006-03-30 Sloan-Kettering Institute For Cancer Research Analogues d'isomigrastatine utilises dans le traitement du cancer
WO2006086744A1 (fr) 2005-02-09 2006-08-17 Macusight, Inc. Formulations pour un traitement oculaire
WO2007011880A2 (fr) 2005-07-18 2007-01-25 Minu, L.L.C. Neuro-protection/neuro-stimulation oculaire amelioree
JP2009506063A (ja) 2005-08-24 2009-02-12 リブ−エックス ファーマシューティカルズ,インコーポレイテッド トリアゾール化合物ならびにこれを作製する方法および使用する方法
ES2638427T3 (es) 2005-08-24 2017-10-20 Melinta Therapeutics, Inc. Compuestos de triazol y procedimientos de preparación y uso del mismo
JP5528708B2 (ja) 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
CN106317146B (zh) * 2015-06-18 2019-06-21 沈阳药科大学 双环克拉霉素衍生物及其作为肿瘤细胞增值抑制剂的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6461090A (en) * 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Also Published As

Publication number Publication date
AU1206799A (en) 1999-05-24
TR200001147T2 (tr) 2000-08-21
PL340604A1 (en) 2001-02-12
EP1027060A2 (fr) 2000-08-16
NO20002189D0 (no) 2000-04-27
HUP0100012A2 (hu) 2001-05-28
CN1278178A (zh) 2000-12-27
AR043071A1 (es) 2005-07-20
CA2307850A1 (fr) 1999-05-14
BG104436A (en) 2000-12-29
IL135518A0 (en) 2001-05-20
ZA989885B (en) 1999-05-05
JP2001521891A (ja) 2001-11-13
KR20010031577A (ko) 2001-04-16
BR9813318A (pt) 2000-08-22
WO1999022722A2 (fr) 1999-05-14
WO1999022722A3 (fr) 1999-08-05
HUP0100012A3 (en) 2003-07-28
NO20002189L (no) 2000-06-28

Similar Documents

Publication Publication Date Title
SK6172000A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
AU2014203882B2 (en) Methods for reducing cellular proliferation and treating certain diseases
EP0929563B1 (fr) Cetolides substitues en 6-o possedant une activite antibacterienne
JP2662094B2 (ja) 4″−デオキシエリスロマイシン誘導体
EP1928470A2 (fr) Modulateurs du facteur 1 induit par hypoxie et utilisations associees dans le traitement de troubles oculaires
CA2876074A1 (fr) Derives de seconde generation n-substitues de l'amphotericine b antibiotique antifongique et leurs procedes de preparation et d'utilisation
JP2836964B2 (ja) 16員環マクロライド系抗生物質の誘導体
KR20140139083A (ko) 마크롤라이드계 항생제를 투여하기 위한 비경구 제제
JP2023109937A (ja) 3-置換1,2,4-オキサジアゾールの結晶形態
CN1269803A (zh) 6,9-桥红霉素衍生物
CA2367319A1 (fr) Derives d'erythromycine
JPH08508038A (ja) 16員環マクロライド系抗生物質のアミド誘導体
JPH07110874B2 (ja) エリスロマイシンa誘導体
US6946446B2 (en) Anti-infective agents useful against multidrug-resistant strains of bacteria
JP2003507487A (ja) 抗菌活性を有する9a−アザライド類
JP2004529921A (ja) ロイコマイシンから誘導された9−アミノ−14員環マクロライド
CZ20001524A3 (cs) Farmaceutický přípravek pro léčení nádorů a makulární degenerace
WO2013132014A1 (fr) Dérivés semi-synthétiques de nystatine a1
EP1259923B1 (fr) Agents anti-infectieux utiles contre des souches de bacteries resistant a l'action de plusieurs medicaments
KR20200014880A (ko) 테세탁셀 및 카페시타빈에 대한 투약 일정
US6716820B1 (en) 6-O-substituted bicyclic macrolides
JP2001518475A (ja) 環状亜リン酸およびリン酸塩
JPH06507407A (ja) エリスロマイシン誘導体
JP2020509086A (ja) トリアゾール含有マクロライド及びその眼科的使用
NZ500531A (en) Multicyclic erythromycin derivatives having antibacterial activity